TY - JOUR
T1 - INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATA
AU - Schonfeld, Alexander
AU - Schattner, Amihai
AU - Crespi, Madeleine
AU - Levavi, Hanoch
AU - Shoham, Jacob
AU - Nitke, Schmuel
AU - Wallach, David
AU - Hahn, Talia
AU - Yarden, Ovadia
AU - Doerner, Thomas
AU - Revel, Michet
N1 - Funding Information:
This work was supported by InterYeda Ltd, Israel.
PY - 1984/5/12
Y1 - 1984/5/12
N2 - A two-part study was done to assess the value of human fibroblast interferon (IFN-β) in the treatment of condylomata acuminata. The first part was an open study of different IFN-β preparations, which showed that intramuscular injection was the most suitable mode of administration of IFN-β. In the double-blind placebo section 22 patients were given injections of 2×106 units IFN-β or placebo for 10 consecutive days and followed up for 3 months. In 9 of the 11 in the IFN-β group and 2 in the placebo group lesions disappeared from about 5 weeks after completion of the course of injections. After 3 months 8 of the non-responders were given a course of IFN-β and all responded to treatment. None of those who had responded has had a recurrence, the disease-free period now being 12 months. Changes in (2'-5') oligo A synthetase levels in white blood cells confirm that intramuscular injections of IFN-β produce a systemic response.
AB - A two-part study was done to assess the value of human fibroblast interferon (IFN-β) in the treatment of condylomata acuminata. The first part was an open study of different IFN-β preparations, which showed that intramuscular injection was the most suitable mode of administration of IFN-β. In the double-blind placebo section 22 patients were given injections of 2×106 units IFN-β or placebo for 10 consecutive days and followed up for 3 months. In 9 of the 11 in the IFN-β group and 2 in the placebo group lesions disappeared from about 5 weeks after completion of the course of injections. After 3 months 8 of the non-responders were given a course of IFN-β and all responded to treatment. None of those who had responded has had a recurrence, the disease-free period now being 12 months. Changes in (2'-5') oligo A synthetase levels in white blood cells confirm that intramuscular injections of IFN-β produce a systemic response.
UR - https://www.scopus.com/pages/publications/0021348217
U2 - 10.1016/S0140-6736(84)91450-8
DO - 10.1016/S0140-6736(84)91450-8
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0021348217
SN - 0140-6736
VL - 323
SP - 1038
EP - 1042
JO - The Lancet
JF - The Lancet
IS - 8385
ER -